Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Debt: 2023-2024

Historic Total Debt for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $13.4 million.

  • BioLineRx's Total Debt fell 61.97% to $11.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.2 million, marking a year-over-year decrease of 61.97%. This contributed to the annual value of $13.4 million for FY2024, which is 37.49% up from last year.
  • Latest data reveals that BioLineRx reported Total Debt of $13.4 million as of FY2024, which was up 37.49% from $9.8 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Total Debt registered a high of $13.4 million during FY2024, and its lowest value of $9.8 million during FY2023.
  • Moreover, its 2-year median value for Total Debt was $11.6 million (2023), whereas its average is $11.6 million.
  • Data for BioLineRx's Total Debt shows a peak YoY spiked of 37.49% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Total Debt (Yearly) stood at $9.8 million in 2023, then soared by 37.49% to $13.4 million in 2024.